Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: A randomized, double-blind, placebo-controlled trial

Susan L. Greenspan, Ronald D. Emkey, Henry G. Bone, Stuart R. Weiss, Norman H. Bell, Robert W. Downs, Clark McKeever, Sam S. Miller, Michael Davidson, Michael A. Bolognese, Anthony L. Mulloy, Norman Heyden, Mei Wu, Amarjot Kaur, Antonio Lombardi

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

Background: Combination therapy with alendronate and estrogen for 2 years increases bone mineral density at the spine and hip more than does therapy with either agent alone. Changes in bone mineral density after discontinuation of therapy have not been compared directly. Objective: To determine the rate of bone loss when therapy with alendronate, estrogen, or both agents is discontinued. Design: Double-blind, placebo-controlled discontinuation trial. Setting: 18 U.S. centers. Patients: 244 postmenopausal, hysterectomized women 44 to 77 years of age. Intervention: 2 years of therapy with alendronate, 10 mg/d (n = 92); conjugated estrogen, 0.625 mg/d (n = 143); alendronate and conjugated estrogen (n = 140); or placebo (n = 50). At year 3, women were allocated into five groups: Twenty-eight women continued to take placebo and 44 women continued to take combination therapy, but 50 women taking alendronate, 81 taking conjugated estrogen, and 41 taking combination therapy were switched to placebo. Measurements: Bone mineral density and biochemical markers of bone turnover. Results: Women taking alendronate or combination therapy who were switched to placebo for year 3 of the study maintained bone mass. Bone mineral density in these women was 4.1% (Cl, 2.6% to 5.7%) and 6.6% (Cl, 5.0% to 8.2%) higher, respectively, at the spine (P > 0.001 for both treatment comparisons) and 3.5% (Cl, 2.3% to 4.6%) and 3.0% (Cl, 1.8% to 4.2%) higher, respectively, at the trochanter (P > 0.001 for both treatment comparisons) than that in women previously taking estrogen who were switched to placebo. In contrast, women who were taking estrogen and were switched to placebo during year 3 experienced a 4.5% decrease at the spine (95% Cl, -5.0% to -4.0%) and a 2.4% decrease at the trochanter (Cl, -2.7% to -2.1%) (P > 0.001 for both changes). Compared with women who took placebo for 3 years, women who took estrogen for 2 years and were then switched to placebo had a bone mineral density that was 2.9% higher (Cl, 1.2% to 4.6%) at the spine (P ± 0.05) and 2.9% higher (Cl, 1.6% to 4.2%) at the trochanter (P ± 0.001). Changes in biochemical markers during year 3 did not differ among the groups that discontinued active treatment. Conclusions: Accelerated bone loss is seen after withdrawal of estrogen therapy but not after withdrawal of alendronate or combination therapy. The differential effects after withdrawal of therapy should be considered in the management of postmenopausal osteoporosis.

Original languageEnglish (US)
Pages (from-to)875-883
Number of pages9
JournalAnnals of Internal Medicine
Volume137
Issue number11
DOIs
StatePublished - Dec 3 2002

Fingerprint

Alendronate
Postmenopausal Osteoporosis
Estrogens
Placebos
Bone and Bones
Bone Density
Conjugated (USP) Estrogens
Therapeutics
Spine
Femur
Biomarkers
Bone Remodeling

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis : A randomized, double-blind, placebo-controlled trial. / Greenspan, Susan L.; Emkey, Ronald D.; Bone, Henry G.; Weiss, Stuart R.; Bell, Norman H.; Downs, Robert W.; McKeever, Clark; Miller, Sam S.; Davidson, Michael; Bolognese, Michael A.; Mulloy, Anthony L.; Heyden, Norman; Wu, Mei; Kaur, Amarjot; Lombardi, Antonio.

In: Annals of Internal Medicine, Vol. 137, No. 11, 03.12.2002, p. 875-883.

Research output: Contribution to journalArticle

Greenspan, Susan L. ; Emkey, Ronald D. ; Bone, Henry G. ; Weiss, Stuart R. ; Bell, Norman H. ; Downs, Robert W. ; McKeever, Clark ; Miller, Sam S. ; Davidson, Michael ; Bolognese, Michael A. ; Mulloy, Anthony L. ; Heyden, Norman ; Wu, Mei ; Kaur, Amarjot ; Lombardi, Antonio. / Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis : A randomized, double-blind, placebo-controlled trial. In: Annals of Internal Medicine. 2002 ; Vol. 137, No. 11. pp. 875-883.
@article{f007eac13b9d4172bafdcbb011dd8c86,
title = "Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: A randomized, double-blind, placebo-controlled trial",
abstract = "Background: Combination therapy with alendronate and estrogen for 2 years increases bone mineral density at the spine and hip more than does therapy with either agent alone. Changes in bone mineral density after discontinuation of therapy have not been compared directly. Objective: To determine the rate of bone loss when therapy with alendronate, estrogen, or both agents is discontinued. Design: Double-blind, placebo-controlled discontinuation trial. Setting: 18 U.S. centers. Patients: 244 postmenopausal, hysterectomized women 44 to 77 years of age. Intervention: 2 years of therapy with alendronate, 10 mg/d (n = 92); conjugated estrogen, 0.625 mg/d (n = 143); alendronate and conjugated estrogen (n = 140); or placebo (n = 50). At year 3, women were allocated into five groups: Twenty-eight women continued to take placebo and 44 women continued to take combination therapy, but 50 women taking alendronate, 81 taking conjugated estrogen, and 41 taking combination therapy were switched to placebo. Measurements: Bone mineral density and biochemical markers of bone turnover. Results: Women taking alendronate or combination therapy who were switched to placebo for year 3 of the study maintained bone mass. Bone mineral density in these women was 4.1{\%} (Cl, 2.6{\%} to 5.7{\%}) and 6.6{\%} (Cl, 5.0{\%} to 8.2{\%}) higher, respectively, at the spine (P > 0.001 for both treatment comparisons) and 3.5{\%} (Cl, 2.3{\%} to 4.6{\%}) and 3.0{\%} (Cl, 1.8{\%} to 4.2{\%}) higher, respectively, at the trochanter (P > 0.001 for both treatment comparisons) than that in women previously taking estrogen who were switched to placebo. In contrast, women who were taking estrogen and were switched to placebo during year 3 experienced a 4.5{\%} decrease at the spine (95{\%} Cl, -5.0{\%} to -4.0{\%}) and a 2.4{\%} decrease at the trochanter (Cl, -2.7{\%} to -2.1{\%}) (P > 0.001 for both changes). Compared with women who took placebo for 3 years, women who took estrogen for 2 years and were then switched to placebo had a bone mineral density that was 2.9{\%} higher (Cl, 1.2{\%} to 4.6{\%}) at the spine (P ± 0.05) and 2.9{\%} higher (Cl, 1.6{\%} to 4.2{\%}) at the trochanter (P ± 0.001). Changes in biochemical markers during year 3 did not differ among the groups that discontinued active treatment. Conclusions: Accelerated bone loss is seen after withdrawal of estrogen therapy but not after withdrawal of alendronate or combination therapy. The differential effects after withdrawal of therapy should be considered in the management of postmenopausal osteoporosis.",
author = "Greenspan, {Susan L.} and Emkey, {Ronald D.} and Bone, {Henry G.} and Weiss, {Stuart R.} and Bell, {Norman H.} and Downs, {Robert W.} and Clark McKeever and Miller, {Sam S.} and Michael Davidson and Bolognese, {Michael A.} and Mulloy, {Anthony L.} and Norman Heyden and Mei Wu and Amarjot Kaur and Antonio Lombardi",
year = "2002",
month = "12",
day = "3",
doi = "10.7326/0003-4819-137-11-200212030-00008",
language = "English (US)",
volume = "137",
pages = "875--883",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "11",

}

TY - JOUR

T1 - Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis

T2 - A randomized, double-blind, placebo-controlled trial

AU - Greenspan, Susan L.

AU - Emkey, Ronald D.

AU - Bone, Henry G.

AU - Weiss, Stuart R.

AU - Bell, Norman H.

AU - Downs, Robert W.

AU - McKeever, Clark

AU - Miller, Sam S.

AU - Davidson, Michael

AU - Bolognese, Michael A.

AU - Mulloy, Anthony L.

AU - Heyden, Norman

AU - Wu, Mei

AU - Kaur, Amarjot

AU - Lombardi, Antonio

PY - 2002/12/3

Y1 - 2002/12/3

N2 - Background: Combination therapy with alendronate and estrogen for 2 years increases bone mineral density at the spine and hip more than does therapy with either agent alone. Changes in bone mineral density after discontinuation of therapy have not been compared directly. Objective: To determine the rate of bone loss when therapy with alendronate, estrogen, or both agents is discontinued. Design: Double-blind, placebo-controlled discontinuation trial. Setting: 18 U.S. centers. Patients: 244 postmenopausal, hysterectomized women 44 to 77 years of age. Intervention: 2 years of therapy with alendronate, 10 mg/d (n = 92); conjugated estrogen, 0.625 mg/d (n = 143); alendronate and conjugated estrogen (n = 140); or placebo (n = 50). At year 3, women were allocated into five groups: Twenty-eight women continued to take placebo and 44 women continued to take combination therapy, but 50 women taking alendronate, 81 taking conjugated estrogen, and 41 taking combination therapy were switched to placebo. Measurements: Bone mineral density and biochemical markers of bone turnover. Results: Women taking alendronate or combination therapy who were switched to placebo for year 3 of the study maintained bone mass. Bone mineral density in these women was 4.1% (Cl, 2.6% to 5.7%) and 6.6% (Cl, 5.0% to 8.2%) higher, respectively, at the spine (P > 0.001 for both treatment comparisons) and 3.5% (Cl, 2.3% to 4.6%) and 3.0% (Cl, 1.8% to 4.2%) higher, respectively, at the trochanter (P > 0.001 for both treatment comparisons) than that in women previously taking estrogen who were switched to placebo. In contrast, women who were taking estrogen and were switched to placebo during year 3 experienced a 4.5% decrease at the spine (95% Cl, -5.0% to -4.0%) and a 2.4% decrease at the trochanter (Cl, -2.7% to -2.1%) (P > 0.001 for both changes). Compared with women who took placebo for 3 years, women who took estrogen for 2 years and were then switched to placebo had a bone mineral density that was 2.9% higher (Cl, 1.2% to 4.6%) at the spine (P ± 0.05) and 2.9% higher (Cl, 1.6% to 4.2%) at the trochanter (P ± 0.001). Changes in biochemical markers during year 3 did not differ among the groups that discontinued active treatment. Conclusions: Accelerated bone loss is seen after withdrawal of estrogen therapy but not after withdrawal of alendronate or combination therapy. The differential effects after withdrawal of therapy should be considered in the management of postmenopausal osteoporosis.

AB - Background: Combination therapy with alendronate and estrogen for 2 years increases bone mineral density at the spine and hip more than does therapy with either agent alone. Changes in bone mineral density after discontinuation of therapy have not been compared directly. Objective: To determine the rate of bone loss when therapy with alendronate, estrogen, or both agents is discontinued. Design: Double-blind, placebo-controlled discontinuation trial. Setting: 18 U.S. centers. Patients: 244 postmenopausal, hysterectomized women 44 to 77 years of age. Intervention: 2 years of therapy with alendronate, 10 mg/d (n = 92); conjugated estrogen, 0.625 mg/d (n = 143); alendronate and conjugated estrogen (n = 140); or placebo (n = 50). At year 3, women were allocated into five groups: Twenty-eight women continued to take placebo and 44 women continued to take combination therapy, but 50 women taking alendronate, 81 taking conjugated estrogen, and 41 taking combination therapy were switched to placebo. Measurements: Bone mineral density and biochemical markers of bone turnover. Results: Women taking alendronate or combination therapy who were switched to placebo for year 3 of the study maintained bone mass. Bone mineral density in these women was 4.1% (Cl, 2.6% to 5.7%) and 6.6% (Cl, 5.0% to 8.2%) higher, respectively, at the spine (P > 0.001 for both treatment comparisons) and 3.5% (Cl, 2.3% to 4.6%) and 3.0% (Cl, 1.8% to 4.2%) higher, respectively, at the trochanter (P > 0.001 for both treatment comparisons) than that in women previously taking estrogen who were switched to placebo. In contrast, women who were taking estrogen and were switched to placebo during year 3 experienced a 4.5% decrease at the spine (95% Cl, -5.0% to -4.0%) and a 2.4% decrease at the trochanter (Cl, -2.7% to -2.1%) (P > 0.001 for both changes). Compared with women who took placebo for 3 years, women who took estrogen for 2 years and were then switched to placebo had a bone mineral density that was 2.9% higher (Cl, 1.2% to 4.6%) at the spine (P ± 0.05) and 2.9% higher (Cl, 1.6% to 4.2%) at the trochanter (P ± 0.001). Changes in biochemical markers during year 3 did not differ among the groups that discontinued active treatment. Conclusions: Accelerated bone loss is seen after withdrawal of estrogen therapy but not after withdrawal of alendronate or combination therapy. The differential effects after withdrawal of therapy should be considered in the management of postmenopausal osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=0037016032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037016032&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-137-11-200212030-00008

DO - 10.7326/0003-4819-137-11-200212030-00008

M3 - Article

C2 - 12458987

AN - SCOPUS:0037016032

VL - 137

SP - 875

EP - 883

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 11

ER -